deferasirox has been researched along with Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Davidoff, AM; Rankovic, Z; Wang, Y; Wu, Q; Yang, J; Young, B | 1 |
| Hao, L; Ji, LN; Mao, ZW; Pan, ZY; Rao, LS; Tan, CP; Zhang, H; Zheng, Y | 1 |
| Alibolandi, M; Babaei, M; Moghadam, SMM; Mosafer, J; Ramezani, M; Saljooghi, AS | 1 |
| Adamaki, M; Athanasiadou, A; Ktena, YP; Lambrou, G; Moschovi, M | 1 |
| Bedford, MR; Ford, SJ; Horniblow, RD; Iqbal, TH; Tselepis, C | 1 |
| Amanlou, M; Arabzadeh, AJ; Ardestani, MS; Delbaz, SA; Ebrahimi, SE; Javidi, A; Mahian, H; Rad, AM | 1 |
| Ohyashiki, K | 1 |
3 review(s) available for deferasirox and Neoplasms
| Article | Year |
|---|---|
Recent Advances with KDM4 Inhibitors and Potential Applications.
Topics: Enzyme Inhibitors; Histone Demethylases; Humans; Jumonji Domain-Containing Histone Demethylases; Neoplasms | 2022 |
Iron chelation in the treatment of cancer: a new role for deferasirox?
Topics: Animals; Antineoplastic Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Neoplasms; Pyridones; Triazoles | 2013 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
1 trial(s) available for deferasirox and Neoplasms
| Article | Year |
|---|---|
Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
Topics: Adolescent; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hemosiderosis; Humans; Infant; Iron; Iron Chelating Agents; Male; Neoplasms; Transfusion Reaction; Triazoles; Young Adult | 2013 |
3 other study(ies) available for deferasirox and Neoplasms
| Article | Year |
|---|---|
Recoding the Cancer Epigenome by Intervening in Metabolism and Iron Homeostasis with Mitochondria-Targeted Rhenium(I) Complexes.
Topics: Animals; Apoptosis; Cell Line, Tumor; Coordination Complexes; Deferasirox; Drug Evaluation, Preclinical; Epigenomics; Histones; Humans; Iron; Iron Chelating Agents; Methylation; Mice; Mitochondria; Neoplasms; Reactive Oxygen Species; Receptors, Antigen, T-Cell; Rhenium; RNA Polymerase II; Signal Transduction | 2020 |
Fabrication of deferasirox-decorated aptamer-targeted superparamagnetic iron oxide nanoparticles (SPION) as a therapeutic and magnetic resonance imaging agent in cancer therapy.
Topics: Animals; Antineoplastic Agents; Aptamers, Nucleotide; Cell Line, Tumor; CHO Cells; Contrast Media; Cricetulus; Deferasirox; Female; Humans; Immobilized Nucleic Acids; Iron Chelating Agents; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice, Inbred BALB C; Neoplasms; Precision Medicine; Propylamines; Silanes | 2021 |
Gadolinium-deferasirox-D-glucosamine: novel anti-tumor and MR molecular (theranostic) imaging agent.
Topics: Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Chromatography, Thin Layer; Contrast Media; Deferasirox; Disease Models, Animal; Gadolinium; Glucosamine; Glucose; Hexokinase; Humans; Magnetic Resonance Imaging; Mice, Nude; Microscopy, Fluorescence; Neoplasms; Phosphorylation; Radionuclide Imaging; Radiopharmaceuticals; Rats; Time Factors; Triazoles; Tumor Necrosis Factor-alpha | 2013 |